Kiromic Biopharma Inc (KRBP NASDAQ) stock market data APIs

$0.0405 0(0%)
as of June 13, 2025
Try our APIs with free plan!

Kiromic Biopharma Inc Financial Data Overview

Price chart is built with Anychart

Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, engages in the utilization of non-engineered an engineered allogeneic Gamma Delta T (GDT) cell technologies to develop therapies for solid tumors in the United States. The company's lead product candidate is the Deltacel-01, which is in Phase 1 clinical trial, in combination with low-dose targeted radiation for patients with non-small cell lung cancer. It also develops Isocel, which is clinical trial in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; Procel, which is in clinical trial in combination with low-dose radiation to treat PD-L1 positive solid malignancies; ALEXIS-ISO-1, which is in clinical trial to evaluate Isocel in patients with Mesothelin Isoform 2 positive solid malignancies; and ALEXIS-PRO-1, which is in clinical trial to evaluate Procel in patients with PD-L1 positive solid malignancies. It has a license agreement with Longwood University. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas. On March 21, 2025, Kiromic BioPharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

Prev. Close 0.0405
Open 0.0405
High 0.0405
Low 0.0405
52 wk Range 0.0358-2.68
Market Cap 215 K
Shares Outstanding 2 653 K
EPS -4.2762
Beta 1.659

Why to choose EODHD?

Prices start at $19.99

24/7 Live support

Robust, powerful and reliable data

API Simplicity of a few lines of code


Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW

Get Kiromic Biopharma Inc data using free add-ons & libraries


Get Kiromic Biopharma Inc Fundamental Data

Kiromic Biopharma Inc Fundamental data includes:

  • Net Revenue:
  • EBITDA: -21 540 000
  • Earnings Per Share:
  • Income Statements
  • Balance Sheets
  • Cash flows

Plans with Fundamental data

Starting from

$ 59.99 /mo.
COMPARE PLANS

End-of-day & Earnings data

Get Kiromic Biopharma Inc Earnings data

Calendar & News package for

$ 19.99 /mo.

What’s included:

  • Latest Release: 2023-11-14
  • EPS/Forecast: NaN
GET THE PACKAGE

Get Kiromic Biopharma Inc End-of-day data

EOD Historical Data package for

$ 19.99 /mo.

What’s included:

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
GET THE PACKAGE

Kiromic Biopharma Inc News

Lifshitz Law PLLC Announces Investigations of FMIA, SUMO, KRBP, and HYRE New

Lifshitz Law PLLC Announces Investigations of FMIA, SUMO, KRBP, and HYRE

NEW YORK, Feb. 25, 2023 (GLOBE NEWSWIRE) -- First Miami Bancorp, Inc. (OTC: FMIA) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale ...

Gainey McKenna & Egleston Filed The First Class Action Lawsuit Against Kiromic BioPharma, Inc. (KRBP); The Class Period Has Been Enlarged from June 25, 2021 to February 2, 2022; And The Motion Deadline For Lead Plaintiff Is Today

Gainey McKenna & Egleston Filed The First Class Action Lawsuit Against Kiromic BioPharma, Inc. (KRBP); The Class Period Has Been Enlarged from June 25, 2021 to February 2, 2022; And The Motion Deadline For Lead Plaintiff Is Today

NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston filed the first class action lawsuit against Kiromic BioPharma, Inc. (“Kiromic” or the “Company”) (NASDAQ: KRBP) and aga...

Final Deadline: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Filed against Kiromic BioPharma, Inc. (KRBP)

Final Deadline: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Filed against Kiromic BioPharma, Inc. (KRBP)

RADNOR, Pa., Oct. 03, 2022 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United...

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Coinbase, Carvana, Kiromic, and LifeStance and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Coinbase, Carvana, Kiromic, and LifeStance and Encourages Investors to Contact the Firm

NEW YORK, Oct. 02, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of st...

Get Apple Inc fresh news feed via Financial News API

Calendar & News package for

$19.99/mo.

Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW
  • Flexibility: No long-term commitments, just a minimum of one month
  • Instant access: Get your API key and instructions within seconds of subscribing
  • Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.

What’s included:

  • API Calls per Day: 100 000/day
  • API Requests per Min.: 1000/minute
  • Type of Usage: Personal use

Data access:

Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.

GET THE PACKAGE
Chat